Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SLC6A1 | P30531 | 4/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1361559 | 0.88 | S1PR5 (0.43) | ALDH1A1LMNACYP1A2SMN1; SMN2 | |
| SCHEMBL1609328 | 0.81 | SMN1; SMN2 (0.54) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL3865049 | 0.81 | SLC6A1 (0.55) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL28959996 | 0.81 | BCHE (0.55) | CYP1A2CYP2D6CYP2C9TSHRNFKB1 | |
| SCHEMBL4759542 | 0.81 | ALDH1A1 (0.50) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL740141 | 0.81 | SMN1; SMN2 (0.54) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL771607 | 0.81 | SMN1; SMN2 (0.54) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL28613250 | 0.80 | SLC6A11 (0.52) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 | |
| SCHEMBL9396978 | 0.80 | HDAC8 (0.47) | ALDH1A1TSHR | |
| SCHEMBL3839597 | 0.80 | SLC6A11 (0.52) | ALDH1A1SLC6A1LMNACYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | JAPAN TOBACCO INC. | 2008-10-02 | — | — | US | disclosed |
| EP-1694638-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | Japan Tobacco, Inc. (JP) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005058808-A1 | N-SUBSTITUTED-N-SULFONYLAMINOCYCLOPROPANE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2005-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242656-A1 | N-Substituted-N-Sulfonylaminocyclopropane Compounds and Pharmaceutical Use Thereof | MMP13, MMP11, MMP3 | ALDH1A1 425/4885SLC6A1 1618/4885LMNA 1749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.